|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Tanaka Precious Metals Succeeds in Development of High-sensitivity In-vitro Diagnostic Kit; Expected to Contribute to Early Discovery of Prostate Cancer
9/7/2010 2:32:54 PM
Tokyo, Sept 3, 2010 (JCN Newswire) - Tanaka Holdings Co., Ltd. (Holding company of Tanaka Precious Metals, Head office: Marunouchi, Chiyoda-ku, Tokyo; President & CEO: Hideya Okamoto) today announced that Tanaka Kikinzoku Kogyo K.K. (Head office: Marunouchi, Chiyoda-ku, Tokyo; President & CEO: Hideya Okamoto), which operates the Tanaka Precious Metals's manufacturing business, succeeded in the development of a "high-sensitivity in-vitro diagnostic kit using colloidal gold" which the Japan Science and Technology Agency (Headquarters: Kawaguchi-shi, Saitama; President: Koichi Kitazawa; JST) had established as a development theme for the Risk-Taking Fund for Technology Development.
|
|
|
|
|
|
|
|
|
|
|